CRSP - CRISPRセラピュ―ティクス （CRISPR Therapeutics AG） CRISPRセラピュ―ティクス

Gainers: HashiCorp (HCP) +14%. lululemon athletica (LULU) +10%

CRISPR Therapeutics (NASDAQ: CRSP ) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a market capitalization of $5.08 billion. Buying $100 In CRSP: If … Full story available on Benzinga.com

ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in September.

Shares of Cathie Wood’s flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ) closed the week down about 2.5%, losing out on earlier gains during the week. However, retail investors haven’t lost hope in ARKK, or Cathie Wood just yet. In the five trading days that ended Aug. 15, investors poured $54.2 million into ARKK, the most in a five-day span since May. The ETF is still down over 50% year-to-date (YTD), even after a significant rally from its June lows. Cathie Wood continues to hold her highest conviction holdings, such as Tesla (NASDAQ: TSLA ) and Teladoc (NYSE: TDOC ). At the same time, she has sold off shares of lower conviction holdings in favor of new names. Let’s get into the details. 5 Stocks That Cathie Wood Sold This Week 1. Signify Health (SGFY) Ark Invest continued its sales of Signify Health (NYSE: SGFY ) for a third straight week. This week, ARKK and the ARK Genomic Revolution ETF (BATS: ARKG ) sold off a total of 3.14 million shares . Earlier this week, it was reported that four companies, including CVS (NYSE: CVS ) and UnitedHealth (NYSE: UNH ), were competing to acquire the healthcare company.

Crispr Therapeutics has given back its August gains as the market digested the significant buying momentum from its June lows. Read more about CRSP stock here.

I’ve written before about how biotech is the biggest technology trend of our kids’ generation . Naturally, that means many people are looking for the best biotech stocks to buy. But as with the PC industry of my time, finding long-term winners is difficult. Back in the early 1980s, dozens of companies entered the PC market, many of them huge for their time. IBM (NYSE: IBM ) was the bet everyone made. But the BUNCH — Burroughs, Univac, NCR (NYSE: NCR ), Control Data and Honeywell (NASDAQ: HON ), were all involved. Almost all of them gave way to newcomers Apple (NASDAQ: AAPL ) and Microsoft (NASDAQ: MSFT ). Apple went public in 1980 and Microsoft in 1986. Similarly, there are huge companies involved in today’s biotech boom. But size is no guarantee of future leadership. There are also big differences between today’s boom and the one that came before. Regulation — the need for drug or device approval — is just one of them. An investor is thus wise to spread their bets and be ready to bail at the first sign of failure.

Someone with a lot of money to spend has taken a bearish stance on CRISPR Therapeutics (NASDAQ: CRSP ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with CRSP, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 22 uncommon options trades for CRISPR Therapeutics. This isn''t normal. The overall sentiment of these big-money traders is split between 45% bullish and 54%, bearish. Out of all of the special options we uncovered, 10 are puts, for a total amount of $376,839, and 12 are calls, for a total amount of $474,817. What''s The Price Target? Taking into account the Volume and Open … Full story available on Benzinga.com

In the last trading session, 3.02 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 1.90. With the company’s per share price at $70.60 changed hands at $6.81 or 10.68% during last session, the market valuation stood at $5.21B. CRSP’s last price was a discount, traded about -124.16% off its 52-week … CRISPR Therapeutics AG (NASDAQ: CRSP): Today’s Most-Watched Stocks Read More »

CRISPR Therapeutics'' price action remains close to its near-term resistance. Why do we believe CRSP stock proffers an opportunity to cut exposure? Find out.

CRISPR Therapeutics AG (NASDAQ:CRSP) shares, rose in value on Thursday, 06/23/22, with the stock price up by 8.69% to the previous day’s close as strong demand from buyers drove the stock to $65.15. Actively observing the price movement in the last trading, the stock closed the session at $59.94, falling within a range of $57.78 … CRISPR Therapeutics AG (NASDAQ: CRSP): Overvalued In Comparison To Others? Read More »

Crispr Therapeutics AG (NASDAQ:CRSP) is a Swiss-American gene editing biotech company developing gene-based medicines. The company’s technology targets specific DNA sequences to modify, delete or correct them. The company’s platform focuses primarily on ex-Vivo programs that target sickle cell disease, β-thalassemia and B-cell malignancies. The lead program targeting sickle cell disease and β-thalassemia has entered […]

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association (EHA) Congress. Vertex also announced three abstracts accepted for poster presentation at EHA. Late-breaking abstract #LB2367 entitled “Efficacy and Safety of A Single Dose of CTX001

BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) today announced new late-breaking clinical data accepted for oral presentation at the 2022 European Hematology Association (EHA) Congress. Vertex also announced three abstracts accepted for poster presentation at EHA. Late-breaking abstract #LB2367 entitled “Efficacy and Safety of A Single Dose of CTX001 For Transfusion-Dependent Βeta-Thalassem

FinancialNewsMedia.com News Commentary PALM BEACH, Fla. , May 18, 2022 /PRNewswire/ -- The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation . Here we discuss the FDA''s Orphan Drug Designation program in reference to AbbVie (NYSE: ABBV ), Crispr Therapeutics AG (NASDAQ: CRSP ), Cytokinetics, Inc. (NASDAQ: CYTK ), and Cardiol Therapeutics (NASDAQ: CRDL ) (TSX: CRDL ). The Orphan Drug Designation program encourages progress in battling rare diseases and conditions. For drug companies carrying out the research and development, the designation brings several incentives, including: Typically obtain high reimbursement levels Exemption from certain FDA fees Potential seven years of market exclusivity after approval ORPHAN DRUG DESIGNATIONS The FDA recently granted Orphan Drug Designation to epcoritamab, a drug developed by Genmab and AbbVie (NYSE: ABBV ) to treat follicular lymphoma. AbbVie is responsible for further global commercialization.

Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ: CRSP ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 5 0 0 Last 30D 0 0 1 0 0 1M Ago 2 4 3 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 1 0 0 These 11 analysts have an average price target of $98.45 versus the current price of CRISPR Therapeutics at $53.45, implying upside. Below is a summary of how these 11 analysts rated CRISPR Therapeutics over the past 3 … Full story available on Benzinga.com